Compare GSL & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | MGTX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Greece | United States |
| Employees | 7 | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | N/A | 2018 |
| Metric | GSL | MGTX |
|---|---|---|
| Price | $41.84 | $13.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $44.00 | $24.57 |
| AVG Volume (30 Days) | 304.3K | ★ 490.2K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $27.28 | $6.62 |
| 52 Week High | $44.69 | $15.35 |
| Indicator | GSL | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 61.02 |
| Support Level | $37.00 | $7.04 |
| Resistance Level | $42.70 | $15.35 |
| Average True Range (ATR) | 1.10 | 0.52 |
| MACD | -0.26 | 0.06 |
| Stochastic Oscillator | 3.93 | 89.37 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.